Short description
Arocell develops and commercializes new and unique biomarker tests that can be used in the prognosis, monitoring, and follow-up of cancer.
Description
Arocell develops and commercializes new and unique biomarker tests that can be used in the prognosis, monitoring, and follow-up of cancer. It has developed a test, the TK 210 ELISA for measuring the enzyme TK1, which is a protein that is elevated in the blood when there is increased cell turnover (cell growth and cell death) within the patient.
The company was established in 2003 and is based in Uppsala, Sweden.
Total funding
$$3123123
Sign in for full access
Location
Uppsala, Uppsala Lan, Sweden, Europe
Founded on
January 1, 2003
Non-profit?
No
Acquired?
No
Employees count
11-50
Investors
Cannot Access
Sign in for full access
Founders
Bernhard Tribukait, Ellen He, Staffan Eriksson, Sven Skog